Orgenesis (ORGS) Competitors $2.27 -0.22 (-8.84%) As of 04/24/2025 01:22 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsSustainabilityTrendsBuy This Stock ORGS vs. OTLK, AVTX, CYCC, STRO, IPSC, MURA, QNCX, KPTI, FBRX, and IMMXShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Outlook Therapeutics (OTLK), Avalo Therapeutics (AVTX), Cyclacel Pharmaceuticals (CYCC), Sutro Biopharma (STRO), Century Therapeutics (IPSC), Mural Oncology (MURA), Quince Therapeutics (QNCX), Karyopharm Therapeutics (KPTI), Forte Biosciences (FBRX), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Outlook Therapeutics Avalo Therapeutics Cyclacel Pharmaceuticals Sutro Biopharma Century Therapeutics Mural Oncology Quince Therapeutics Karyopharm Therapeutics Forte Biosciences Immix Biopharma Orgenesis (NASDAQ:ORGS) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings. Do analysts rate ORGS or OTLK? Outlook Therapeutics has a consensus target price of $10.20, suggesting a potential upside of 558.06%. Given Outlook Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, ORGS or OTLK? Orgenesis has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Does the media refer more to ORGS or OTLK? In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Outlook Therapeutics'average media sentiment score. Company Overall Sentiment Orgenesis Neutral Outlook Therapeutics Neutral Does the MarketBeat Community prefer ORGS or OTLK? Outlook Therapeutics received 164 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 71.12% of users gave Outlook Therapeutics an outperform vote. CompanyUnderperformOutperformOrgenesisOutperform Votes1100.00% Underperform VotesNo VotesOutlook TherapeuticsOutperform Votes16571.12% Underperform Votes6728.88% Do insiders and institutionals hold more shares of ORGS or OTLK? 22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by insiders. Comparatively, 4.8% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, ORGS or OTLK? Orgenesis has higher revenue and earnings than Outlook Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K16.46-$55.36MN/AN/AOutlook TherapeuticsN/AN/A-$75.37M-$7.42-0.21 Is ORGS or OTLK more profitable? Outlook Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Outlook Therapeutics N/A N/A -225.12% SummaryOrgenesis beats Outlook Therapeutics on 7 of the 12 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.89M$6.59B$5.40B$7.70BDividend YieldN/A3.20%5.44%4.32%P/E RatioN/A7.0522.1918.31Price / Sales16.46273.45401.66107.05Price / CashN/A65.6738.2034.62Price / Book-0.346.506.854.25Net Income-$55.36M$142.50M$3.20B$247.51M7 Day Performance3.65%8.32%5.91%6.33%1 Month Performance-15.30%-5.61%-4.20%-3.33%1 Year PerformanceN/A0.11%18.07%5.15% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$2.27-8.8%N/AN/A$10.89M$662,000.000.00150OTLKOutlook Therapeutics1.3246 of 5 stars$1.47+1.4%$10.20+593.9%-81.1%$47.07MN/A-0.2020AVTXAvalo Therapeutics3.1176 of 5 stars$4.41flat$33.00+648.3%-65.6%$47.06M$441,000.000.0040Gap UpCYCCCyclacel Pharmaceuticals2.5284 of 5 stars$0.21-6.6%$11.00+5,110.8%-90.0%$46.88M$74,000.00-0.0214Dividend AnnouncementAnalyst ForecastGap DownSTROSutro Biopharma3.9086 of 5 stars$0.55+5.3%$6.63+1,099.5%-62.5%$46.59M$62.04M-0.34240High Trading VolumeIPSCCentury Therapeutics2.0974 of 5 stars$0.54-0.7%$4.40+714.8%-82.1%$46.46M$6.59M-0.29170News CoverageHigh Trading VolumeMURAMural Oncology2.5358 of 5 stars$2.69-0.4%$13.00+383.3%-26.7%$46.34MN/A-0.29119QNCXQuince Therapeutics2.0189 of 5 stars$1.05+6.0%$8.00+661.9%+6.1%$46.29MN/A-0.8560Gap UpKPTIKaryopharm Therapeutics3.3823 of 5 stars$5.40+9.1%$57.50+964.8%-63.5%$46.28M$145.24M-5.29380FBRXForte Biosciences2.6617 of 5 stars$7.01-4.5%$32.50+363.6%+24,407.0%$46.14MN/A-0.435IMMXImmix Biopharma2.2409 of 5 stars$1.66+1.2%$7.00+321.7%-17.8%$46.02MN/A-1.959Positive NewsGap Up Related Companies and Tools Related Companies Outlook Therapeutics Alternatives Avalo Therapeutics Alternatives Cyclacel Pharmaceuticals Alternatives Sutro Biopharma Alternatives Century Therapeutics Alternatives Mural Oncology Alternatives Quince Therapeutics Alternatives Karyopharm Therapeutics Alternatives Forte Biosciences Alternatives Immix Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORGS Stock Free ORGS Stock Alerts